AKT1 and neoplasm: These results suggested that endostatin 33 peptide inhibits the PI3K-Akt pathway via the targeted inhibition of integrin α6β1, and the inhibition of the PI3K-Akt pathway in turn inhibits EMT and MMPs expression, thus exerting an anti-tumor biological effect in PCa.